Frazier Life Sciences Management L.P. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 44.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 885,165 shares of the company’s stock after acquiring an additional 271,122 shares during the […]
KPP Advisory Services LLC boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 17.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,196 shares of the company’s stock after purchasing an additional 1,675 shares during the quarter. KPP Advisory Services LLC’s […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $92.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.79% from the company’s previous close. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts also recently issued reports about the stock. Wedbush dropped their price objective […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also recently issued research reports about the stock. […]